$APLT
Applied Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000155837021015654 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.39M $10.83M $10.02M
YoY Change 14.7% 8.11% 204.56%
% of Gross Profit
Research & Development $15.72M $17.60M $19.95M
YoY Change 13.86% -11.77% 167.72%
% of Gross Profit
Depreciation & Amortization $1.000K
YoY Change
% of Gross Profit
Operating Expenses $27.11M $28.43M $29.97M
YoY Change 14.16% -5.12% 178.74%
Operating Profit -$28.43M -$29.97M
YoY Change -5.12%
Interest Expense $234.0K $76.00K $131.0K
YoY Change 95.0% -41.98% 336.67%
% of Operating Profit
Other Income/Expense, Net -$279.0K $12.00K $121.0K
YoY Change 298.57% -90.08%
Pretax Income -$27.16M -$28.42M -$29.84M
YoY Change 14.64% -4.77% 178.62%
Income Tax
% Of Pretax Income
Net Earnings -$27.16M -$28.42M -$29.84M
YoY Change 14.64% -4.78% 178.66%
Net Earnings / Revenue
Basic Earnings Per Share -$1.09 -$1.33
Diluted Earnings Per Share -$1.046M -$1.09 -$1.33
COMMON SHARES
Basic Shares Outstanding 26.22M 26.18M 22.43M
Diluted Shares Outstanding 26.18M 22.43M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $80.82M $108.8M $116.5M
YoY Change -16.51% -6.61% 253.03%
Cash & Equivalents $53.89M $70.21M $48.68M
Short-Term Investments $26.94M $38.60M $67.80M
Other Short-Term Assets $471.0K $473.0K $6.400M
YoY Change 68.21% -92.61% 56.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $88.39M $116.9M $122.9M
YoY Change -13.84% -4.85% 232.16%
LONG-TERM ASSETS
Property, Plant & Equipment $1.298M $1.404M $1.800M
YoY Change -23.65% -22.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.498M $1.604M $1.900M
YoY Change -21.69% -15.58% 533.33%
TOTAL ASSETS
Total Short-Term Assets $88.39M $116.9M $122.9M
Total Long-Term Assets $1.498M $1.604M $1.900M
Total Assets $89.89M $118.5M $124.8M
YoY Change -13.98% -5.01% 234.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.461M $9.170M $1.900M
YoY Change 1378.28% 382.63% 11.76%
Accrued Expenses $16.01M $21.02M $17.80M
YoY Change -19.93% 18.07% 286.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.46M $30.84M $20.50M
YoY Change 24.62% 50.45% 215.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $891.0K $1.003M $1.400M
YoY Change -31.46% -28.36%
Total Long-Term Liabilities $891.0K $1.003M $1.400M
YoY Change -33.11% -28.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.46M $30.84M $20.50M
Total Long-Term Liabilities $891.0K $1.003M $1.400M
Total Liabilities $27.35M $31.85M $21.90M
YoY Change 21.21% 45.42% 236.92%
SHAREHOLDERS EQUITY
Retained Earnings -$266.3M -$239.2M
YoY Change 65.69%
Common Stock $3.000K $3.000K
YoY Change 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $62.54M $86.70M $102.9M
YoY Change
Total Liabilities & Shareholders Equity $89.89M $118.5M $124.8M
YoY Change -13.98% -5.01% 234.58%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$27.16M -$28.42M -$29.84M
YoY Change 14.64% -4.78% 178.66%
Depreciation, Depletion And Amortization $1.000K
YoY Change
Cash From Operating Activities -$26.94M -$15.67M -$20.69M
YoY Change 18.43% -24.29% 163.9%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $11.81M $8.518M -$30.24M
YoY Change -58.48% -128.17% 52.11%
Cash From Investing Activities $11.81M $8.518M -$30.24M
YoY Change -58.48% -128.17% 52.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.184M -1.080M -1.240M
YoY Change -138.32% -12.9% 327.59%
NET CHANGE
Cash From Operating Activities -26.94M -15.67M -20.69M
Cash From Investing Activities 11.81M 8.518M -30.24M
Cash From Financing Activities -1.184M -1.080M -1.240M
Net Change In Cash -16.32M -8.227M -52.17M
YoY Change -285.87% -84.23% 86.25%
FREE CASH FLOW
Cash From Operating Activities -$26.94M -$15.67M -$20.69M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26177079
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22426203
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25472590
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21790207
dei Entity Central Index Key
EntityCentralIndexKey
0001697532
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26177079
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22426203
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25472590
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21790207
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22493661
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26214399
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-28418000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-29844000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-78425000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-70272000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.22
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28418000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29844000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78425000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70272000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.22
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38898
dei Entity Registrant Name
EntityRegistrantName
Applied Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3405262
dei Entity Address Address Line1
EntityAddressAddressLine1
545 Fifth Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1400
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
220-9226
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
APLT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26215514
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70207000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57466000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
38595000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
39363000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8141000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5764000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
116943000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
102593000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1404000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1712000
CY2021Q3 aplt Security Deposit And Leasehold Improvements Net
SecurityDepositAndLeaseholdImprovementsNet
200000
CY2020Q4 aplt Security Deposit And Leasehold Improvements Net
SecurityDepositAndLeaseholdImprovementsNet
201000
CY2021Q3 us-gaap Assets
Assets
118547000
CY2020Q4 us-gaap Assets
Assets
104506000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
436000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
406000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9170000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
640000
CY2021Q3 aplt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
21237000
CY2020Q4 aplt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
20189000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30843000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21235000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1003000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1332000
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1003000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1332000
CY2021Q3 us-gaap Liabilities
Liabilities
31846000
CY2020Q4 us-gaap Liabilities
Liabilities
22567000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26214399
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22493661
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
326108000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
242780000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-254000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-112000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239156000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160731000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
86701000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
81939000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
118547000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104506000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17597000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19945000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46846000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47974000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10833000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10020000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31658000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22744000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
28430000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
29965000
us-gaap Operating Expenses
OperatingExpenses
78504000
us-gaap Operating Expenses
OperatingExpenses
70718000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28430000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29965000
us-gaap Operating Income Loss
OperatingIncomeLoss
-78504000
us-gaap Operating Income Loss
OperatingIncomeLoss
-70718000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
76000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
131000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
321000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
435000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-64000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-242000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
121000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
79000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
446000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28418000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-29844000
us-gaap Net Income Loss
NetIncomeLoss
-78425000
us-gaap Net Income Loss
NetIncomeLoss
-70272000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28418000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29844000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78425000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70272000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.22
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26177079
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22426203
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25472590
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21790207
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28418000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-29844000
us-gaap Net Income Loss
NetIncomeLoss
-78425000
us-gaap Net Income Loss
NetIncomeLoss
-70272000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-69000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-65000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-142000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-92000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-69000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-65000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-142000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-92000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28487000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29909000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78567000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70364000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
32607000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1331000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12369000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
91000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
155828000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1342000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1737000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-28059000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-118000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
130204000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
242000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2403000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-29844000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-65000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
102940000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
81939000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67000
CY2021Q1 aplt Stock Options Exercised For Common Stock Not Yet Issued Value
StockOptionsExercisedForCommonStockNotYetIssuedValue
1000
CY2021Q1 aplt Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
69000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2981000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-24179000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-42000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
135221000
CY2021Q2 aplt Stock Issued During Period Value Stock Options Exercised In Prior Period
StockIssuedDuringPeriodValueStockOptionsExercisedInPriorPeriod
1000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
341000
CY2021Q2 aplt Stock Options Exercised For Common Stock Not Yet Issued Value
StockOptionsExercisedForCommonStockNotYetIssuedValue
1000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2702000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-25828000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-31000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
112440000
CY2021Q3 aplt Stock Issued During Period Value Stock Options Exercised In Prior Period
StockIssuedDuringPeriodValueStockOptionsExercisedInPriorPeriod
1000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
103000
CY2021Q3 aplt Stock Options Exercised For Common Stock Not Yet Issued Value
StockOptionsExercisedForCommonStockNotYetIssuedValue
1000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2645000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28418000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-69000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
86701000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-263000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63786000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55459000
us-gaap Profit Loss
ProfitLoss
-78425000
us-gaap Profit Loss
ProfitLoss
-70272000
us-gaap Share Based Compensation
ShareBasedCompensation
8328000
us-gaap Share Based Compensation
ShareBasedCompensation
5471000
aplt Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
308000
aplt Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
281000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-299000
aplt Increase Decrease In Financed Insurance Premium
IncreaseDecreaseInFinancedInsurancePremium
4434000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1107000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3396000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8530000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6739000
aplt Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
149000
aplt Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
11127000
aplt Amortization Of Leasehold Improvements
AmortizationOfLeaseholdImprovements
1000
aplt Amortization Of Insurance Premium
AmortizationOfInsurancePremium
3163000
aplt Amortization Of Insurance Premium
AmortizationOfInsurancePremium
1540000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
109119000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
127558000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5539000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
17109000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
104206000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
62536000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
626000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47913000
aplt Cash Stock Issuance Costs
CashStockIssuanceCosts
702000
aplt Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
74420000
aplt Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
134102000
aplt Proceeds From Financed Insurance Premium
ProceedsFromFinancedInsurancePremium
4434000
aplt Payments For Financing Activities Insurance Premium Down Payment
PaymentsForFinancingActivitiesInsurancePremiumDownPayment
793000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
3534000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1074000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
512000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1665000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
69000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75901000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
133201000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12741000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29829000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57466000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18850000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70207000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48679000
aplt Directors And Officers Insurance Premium Short Term Note
DirectorsAndOfficersInsurancePremiumShortTermNote
-4015000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-142000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
92000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and reliance on third-party manufacturers.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38849000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
256000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
38595000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39475000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
123000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39363000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
300000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
300000
aplt Gross Unrealized Losses Percentage Of Corporate Bond Portfolio Amortized Cost Basis
GrossUnrealizedLossesPercentageOfCorporateBondPortfolioAmortizedCostBasis
0.0065
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
38849000
CY2021Q3 aplt Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Rolling Within One Year
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxRollingWithinOneYear
2000
CY2021Q3 aplt Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Rolling Within One Year
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxRollingWithinOneYear
256000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
38595000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
39475000
CY2020Q4 aplt Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Rolling Within One Year
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxRollingWithinOneYear
11000
CY2020Q4 aplt Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Rolling Within One Year
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxRollingWithinOneYear
123000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
39363000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38849000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
256000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
38595000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39475000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
123000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39363000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
300000
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
64000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
200000
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
256000
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
28356000
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
256000
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
28356000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
123000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
14073000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
123000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
14073000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4529675
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.87
CY2021Q3 aplt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
3925000
CY2020Q4 aplt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2349000
CY2021Q3 aplt Insurance Premium Asset Current
InsurancePremiumAssetCurrent
2733000
CY2020Q4 aplt Insurance Premium Asset Current
InsurancePremiumAssetCurrent
1463000
CY2021Q3 us-gaap Prepaid Rent
PrepaidRent
74000
CY2020Q4 us-gaap Prepaid Rent
PrepaidRent
108000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
86000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
91000
CY2021Q3 aplt Prepaid Commercial And Patient Advocacy
PrepaidCommercialAndPatientAdvocacy
523000
CY2020Q4 aplt Prepaid Commercial And Patient Advocacy
PrepaidCommercialAndPatientAdvocacy
968000
CY2021Q3 aplt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
279000
CY2020Q4 aplt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
500000
CY2021Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
48000
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
5000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
473000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
280000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8141000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5764000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2021Q3 aplt Accrued Pre Clinical And Clinical Expenses Current
AccruedPreClinicalAndClinicalExpensesCurrent
13102000
CY2020Q4 aplt Accrued Pre Clinical And Clinical Expenses Current
AccruedPreClinicalAndClinicalExpensesCurrent
13742000
CY2021Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1974000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1074000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
740000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
511000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1852000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2103000
CY2021Q3 aplt Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
2114000
CY2020Q4 aplt Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
502000
CY2021Q3 aplt Accrued Patent Expenses Current
AccruedPatentExpensesCurrent
798000
CY2020Q4 aplt Accrued Patent Expenses Current
AccruedPatentExpensesCurrent
1704000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
657000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
553000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
21237000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
20189000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
231081
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
20200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.74
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2645000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2403000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8328000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5471000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
31778000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2895866
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.60
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
28630000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1646487
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
21.65
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
51103000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
231081
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.72
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
190436
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2973000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
27872
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
20.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
95
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
44.02
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4542353
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.44
aplt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P8Y8M12D
CY2021Q3 aplt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue
3148000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
aplt Warrants Exercised
WarrantsExercised
27855
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
125618
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
153473
us-gaap Operating Lease Cost
OperatingLeaseCost
126000
us-gaap Operating Lease Cost
OperatingLeaseCost
121000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y29D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0569
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0569
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
128000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
507000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
515000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
423000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1573000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
134000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1439000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-28418000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-29844000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26177079
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22426203
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-78425000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-70272000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25472590
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21790207
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.22

Files In Submission

Name View Source Status
0001558370-21-015654-index-headers.html Edgar Link pending
0001558370-21-015654-index.html Edgar Link pending
0001558370-21-015654.txt Edgar Link pending
0001558370-21-015654-xbrl.zip Edgar Link pending
aplt-20210930.xsd Edgar Link pending
aplt-20210930x10q.htm Edgar Link pending
aplt-20210930x10q_htm.xml Edgar Link completed
aplt-20210930xex31d1.htm Edgar Link pending
aplt-20210930xex31d2.htm Edgar Link pending
aplt-20210930xex32d1.htm Edgar Link pending
aplt-20210930xex32d2.htm Edgar Link pending
aplt-20210930_cal.xml Edgar Link unprocessable
aplt-20210930_def.xml Edgar Link unprocessable
aplt-20210930_lab.xml Edgar Link unprocessable
aplt-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending